Naldemedine for the treatment of opioid-induced constipation in adults with chronic noncancer pain

This review aims to summarize the efficacy data for naldemedine, a member of the novel peripherally acting μ-opioid receptor antagonists (PAMORAs), which gained US FDA approval for the treatment of opioid-induced constipation in adults with chronic noncancer pain-related syndromes in 2017. In Phase...

Full description

Saved in:
Bibliographic Details
Published in:Pain management (London) 2020-09, Vol.10 (5), p.301-306
Main Authors: Liu, Joy J, Quinton, Sarah E, Brenner, Darren M
Format: Article
Language:English
Subjects:
Constipation
Drug withdrawal
Laxatives
Narcotics
opioids
Pain
Pain management
Patients
Pelvis
Polyethylene glycol
Side effects
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This review aims to summarize the efficacy data for naldemedine, a member of the novel peripherally acting μ-opioid receptor antagonists (PAMORAs), which gained US FDA approval for the treatment of opioid-induced constipation in adults with chronic noncancer pain-related syndromes in 2017. In Phase III trials, patients receiving naldemedine were significantly more likely to meet the primary end point ≥3 spontaneous bowel movements/week and an increase of ≥1 spontaneous bowel movement/week from baseline for at least 9/12 weeks compared to placebo (p < 0.0001). The most frequent adverse events were abdominal pain (8%) and diarrhea (7%). Based on available data, naldemedine appears to be an effective and safe first-line therapy for the treatment of opioid-induced constipation in adults with chronic noncancer pain.
ISSN:1758-1869
1758-1877
DOI:10.2217/pmt-2020-0019